Phase I/II clinical trial of novel peptide-based cancer vaccine IMA901 for patients with advanced renal cell carcinoma.
Phase of Trial: Phase I/II
Latest Information Update: 12 May 2016
At a glance
- Drugs IMA 901 (Primary) ; Cyclophosphamide; Granulocyte-macrophage colony-stimulating factors
- Indications Renal cell carcinoma
- Focus Adverse reactions; Therapeutic Use
- 30 Dec 2011 New trial record